The group’s share of profit amounted to 3.3 billion dollars against 112 million a year earlier. DADO RUVIC / REUTERS
The British pharmaceutical giant has unveiled a turnover of 44.4 billion dollars, driven by the integration of Alexion.
British pharmaceutical giant AstraZeneca on Thursday unveiled a sharp rise in profit over one year and sales driven by the integration of Alexion, despite the loss of momentum in revenues linked to the vaccine against covid-19.
The group’s share of profit amounted to 3.3 billion dollars against 112 million a year earlier, for a turnover up 18.5% to 44.4 billion.
TO HAVE ALSO – Covid-19: “By getting vaccinated, we did not save time but we saved lives”, explains Vincent Bordenave